| 摘要 |
The present invention relates to crystalline forms of canagliflozin, processes for their preparation, and their use for the treatment of type 2 diabetes mellitus. A crystalline Form R1of canagliflozin emihydrate. The crystalline Form R1 of canagliflozin hemihydrate of claim 1, characterized by an X-ray powder diffraction peaks having d-spacing values at about 3.1, 3.7, 4.6, and 8.9 A. |
| 申请人 |
SUN PHARMACEUTICAL INDUSTRIES LIMITED |
发明人 |
SANTRA, RAMKINKAR;NAGDA, DEVENDRA, PRAKASH;THAIMATTAM, RAM;ARYAN, SATISH, KUMAR;SINGH, TARUN, KUMAR;PRASAD, MOHAN;GANGULY, SOMENATH;WADHWA, DEEPIKA |
